A clear, funded path: a ~18-month runway to Phase IIb topline data — the defining BD event. Every milestone brings the company closer to an out-licensing deal with a pharma giant.

Milestones

2

Q3 2027

Phase IIb Initiation

4

2029

Out-licensing with Pharma

1

Q4 2026

Phase IIa Results (AML)

3

Q2 2028

Topline IIb · BD Trigger

Use of Proceeds

20%

KRAS

Expansion

5%

G&A

IP

60%

Phase IIb

Clinical

15%

CMC

Manufacturing

Raise target: $35–40M

Series A · ~18-month runway to topline.

Join the Opportunity

Contact Bridges B2B to arrange a call, investor materials and an NDA.

BRIDGES B2B